This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Hypercholesterolemia
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.

Provided treatments

  • Drug: Alirocumab
  • Drug: Rosuvastatin
  • Drug: Ezetimibe
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01730053. The sponsor of the trial is Regeneron Pharmaceuticals and it is looking for 305 volunteers for the current phase.
Official trial title:
A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin